Diaceutics, the diagnostics data analytics and implementation services company, is opening a new regional Asian hub in Singapore.
The company, which was founded by Entrepreneur of the Year finalist Peter Keeling, said that more than 10% of its annual revenues now come from the Asian market and it works with 166 laboratories across the region.
Diaceutics said there is more than 300 targeted oncology drugs in late stage development across the major Asian markets.
From its Asian headquarters, Diaceutics said it will support the launch of and access to precision therapies in China, Japan, Hong Kong, South Korea, Thailand and Taiwan.
Damian Thornton, chief operating officer at Diaceutics, said that with more than half of the world's population residing in Asia, this is a natural step for the company.
"Singapore provides the ideal hub from which to ramp up our work in Asia and the Singapore Economic Development Board (EDB) was instrumental in helping us to establish here.
"We are excited to have a very skilled team of scientists and business people, who share the company's vision of helping to improve patient outcomes through better testing," he added.
